Crossmark

Vitiligo as durvalumab's immune-related adverse event in lung cancer

Crossref DOI link: https://doi.org/10.1016/j.medcli.2021.07.024

Published Print: 2022-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Rogado, Jacobo

Buendía-Castaño, Diego

Alonso-García, Soledad R.
License Information

Text and Data Mining valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01
More Information

This article is maintained by: Elsevier

Article Title: Vitiligo as durvalumab's immune-related adverse event in lung cancer

Journal Title: Medicina Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcli.2021.07.024

Content Type: simple-article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.